SBIR-STTR Award

A Nanodroplet Processor for Advanced Microencapsulated Drug Formulations
Award last edited on: 10/12/2005

Sponsored Program
SBIR
Awarding Agency
NASA : JSC
Total Award Amount
$675,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Donald Ackley

Company Information

Nanotrope Inc

3030 Bunker Hill Street Suite 115B
San Diego, CA 92109
   (858) 270-7992
   donackley@cox.net
   www.nanotrope.com
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2005
Phase I Amount
$75,000
The objective of this proposal is to provide a demonstration of a nanodroplet synthesis of multifunctional liposomes for drug delivery based on immiscible microfluidics processing. In this initial study, the functionality of the liposomes will include (1) the surface functionalized particles for targeting specific cells and (2) the protected packaging of protein therapeutics that may be released upon specific binding of the liposome to a targeted cell. This goal will be accomplished using nanodroplet technology that exploits the properties of immiscible fluids to transform continuous fluid streams into highly monodispersed, isolated droplets with tight control of droplet size and generation rate. The nanoparticles are formed at room temperature with low pressure and shear forces to prevent the denaturation of protein drugs, which will be important for the treatment of major diseases such as heart disease and cancer. Since cells rapidly uptake nanoparticles with sizes less than 500 nm, the major objective for this proposal is demonstrate highly monodisperse particles in this regime. Furthermore, we anticipate that producing such particles in a microgravity environment will lead to an improved fundamental understanding of droplet formation itself and to the production of homogeneously distributed therapeutics in a perfectly spherical nano-particle.

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2006
Phase II Amount
$600,000
During this Phase II program we propose to build on the key aspects of the nanodroplet encapsulation technology to demonstrate optimized formulation and encapsulation of protein drugs. The ability of the nanodroplet generator to produce nanoscale drug "containers" with designer characteristics provides us with a distinct advantage in targeting protein containing vesicles to diseased cells and organs. We plan to target cancerous cells and tumors using our engineered drug vesicles, with specifically designed lipid outer layers as well as targeted surface functionalization to improve drug uptake by the cells, reduce toxicity, and otherwise improve safety and efficacy. The optimized vesicles will result in improved stability and enhanced control of pharmacokinetics in both cell lines and animal models.The nanodroplet platform will be scaled up to produce gram quantities of engineered vesicles with a monodisperse size distribution and a target size of 200nm.